

Instructions for Use SALSA® MLPA® Probemix P335 ALL-IKZF1

See also the MLPA General Protocol, the product description of the SALSA® MLPA® Reagent Kit, and the Coffalyser.Net Reference Manual.

Visit the SALSA® MLPA® Probemix P335 ALL-IKZF1 product page on our website to find Certificates of Analysis and a list of related products.

Product name	SALSA® MLPA® Probemix
	P335 ALL-IKZF1
Version	C2
Catalogue numbers	P335-025R (25 reactions)
	P335-050R (50 reactions)
	P335-100R (100 reactions)
Basic UDI-DI:	n.a.
	Synthetic oligonucleotides,
Ingredients	oligonucleotides purified from bacteria,
-	Tris-HCI, EDTA

Additional Test Components	Catalogue numbers
	EK1-FAM
	EK1-CY5
SALSA® MLPA® Reagent Kit	EK5-FAM
	EK5-CY5
	EK20-FAM

Storage and Shelf Life

Recommended conditions	-25°C	紊
------------------------	-------	---

A shelf life of until the expiry date is guaranteed, also after opening when stored in the original packaging under recommended conditions. For the exact expiry date, see the label on the vial. This product should not be exposed to more than 25 freeze-thaw cycles. Do not use the product if the packaging is damaged or opened. Leave chemicals in original containers. Waste material must be disposed of in accordance with the national and local regulations.



Any serious incident that has occurred in relation to this product should be reported to MRC Holland and the competent authority of the Member State in which the user and/or the patient is located.

Changes in this Product Version:

As compared to version C1, lengths of several probes are adjusted, but no changes in the sequences detected.

1. Intended Purpose

The SALSA MLPA Probemix P335 ALL-IKZF1 is an in vitro diagnostic (IVD)¹ or a research use only (RUO) semi-quantitative manual assay² for the detection of deletions of the *IKZF1* gene for stratification of patients with acute lymphoblastic leukemia (ALL) into prognostic subgroups³. The SALSA MLPA Probemix P335 ALL-IKZF1 is a RUO assay² for the detection of deletions or duplications in B-cell differentiation and cell cycle control genes (*EBF1, CDKN2A/2B, PAX5, ETV6, BTG1* and *RB1*) and in the PAR1 region. This assay is for use on genomic DNA isolated from human peripheral whole blood and bone marrow specimens.

Copy number alterations (CNAs) detected with P335 ALL-IKZF1 should be confirmed with a different technique. In particular, CNAs detected by only a single probe always require confirmation by another method. In the majority of patients, defects in the *IKZF1* gene are deletions, but point mutations can occur which will not be detected by MLPA. It is therefore recommended to use this assay in combination with sequence analysis of the *IKZF1* gene.

Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, clinical genetic evaluation, and counselling, as appropriate. The results of this test should be interpreted by a clinical molecular geneticist or equivalent.

This device is not intended to be used for standalone diagnostic purposes or population screening.

¹ Please note that this probemix is for in vitro diagnostic (IVD) use in the countries specified on page 1 of this product description. In all other countries, the product is for research use only (RUO).

 $^{\rm 2}$ To be used in combination with a SALSA MLPA Reagent Kit and Coffalyser.Net analysis software.

³ Certain probes targeting additional genes included in P335 ALL-IKZF1 may only be used in a research setting. The following table summarises which probes are for IVD use or exclusively restricted to be used in a research setting:

IVD Target	RUO Targets
IKZF1	EBF1, CDKN2A/2B, PAX5, ETV6, BTG1, RB1, and the PAR1 region

2. Sample Requirements

Specimen	50-250 ng purified human genomic DNA, free from heparin, dissolved in 5 μ l TE _{0.1} buffer, pH 8.0-8.5
Collection Method	Standard methods
Extraction Method	 Methods tested by MRC Holland: QIAGEN Autopure LS (automated) and QIAamp DNA mini/midi/maxi kit (manual) Promega Wizard Genomic DNA Purification Kit (manual) Salting out (manual)

Sample Types							
Test Sample	 Provided by user 						
Test Sample	 ≥30% tumour cells (recommended: ≥50%) 						
Reference Samples (Required)	 Provided by user Extraction method, tissue type, DNA concentration and treatment as similar as possible in all test and reference samples. Have a normal copy number and ≤0.10 standard deviation for all probes. At least three* independent reference samples required in each experiment for proper data normalisation. Derived from unrelated male individuals from families without a history of ALL. Should be from healthy male individuals to 						
	more information).						
No-DNA	Provided by user						
Control	• TE _{0.1} buffer instead of	DNA					
(Preferably)	 To check for DNA cont 	tamination					
	 Provided by user if approximation 	olicable, or					
Positive Control Samples (Preferably)	Available from third parties	See the table of positive samples on the probemix product page on our website.					
Validation Samples (Required)	 In the validation experiments of this probemix, DNA samples from healthy male individuals should be used. 						

*When testing >21 samples, include one extra reference for each 7 test sample.



3. Test Procedure

See the MLPA General Protocol.

4. Quality Control, Data Analysis, and Troubleshooting

Qualit	Quality Control Fragments in the Probemix				
Length (nt) Function					
64-70-76-82	DNA quantity control fragments				
88-96	DNA denaturation control fragments				
92	Benchmark fragment				
100	Chromosome X presence control fragment				
105	Chromosome Y presence control fragment				

<u>Coffalyser.Net</u> should be used for data analysis in combination with the appropriate product and lot-specific Coffalyser sheet. See the <u>Coffalyser.Net Reference Manual</u> for details on data analysis and quality control.

For troubleshooting help, see the additional resources offered on our support portal.

5. Interpretation of Results

Determining Typical Values in Normal and Affected Populations

The typical final ratio (FR) values stated in the copy number tables were determined in a validation study with samples containing abnormal copy numbers. The standard deviation of each individual probe over all the reference samples was ≤ 0.10 .

Expected Results of Reference Probes

Final Ratio (FR)	Copy Number	Description
0.80 - 1.20	2	Normal

Typical	Resu	Its of	Probes	: Targe	eting	Two	Copies	s (IKZF1	, EBF1,
CDKN2	A/2B	PAX5	, ETV6,	BTG1	, RB1,	, and	the PA	AR1 regi	ion)

Final Ratio (FR)	Copy Number	Description
0	0	Homozygous deletion
0.40 - 0.65	1	Heterozygous deletion
0.80 - 1.20	2	Normal
1.30 - 1.65	3	Heterozygous gain
1.75 - 2.15	4	Homozygous gain or Heterozygous triplication
All other values	-	Ambiguous

The tables illustrate the relationship between final probe ratio and corresponding copy number. Test results are expected to center around these values. Ambiguous values can indicate a technical problem, but may also reflect a biological cause.

Final ratios are affected both by percentage of tumour cells and by possible subclonality. It is important to use Coffalyser.Net to determine the significance of values found.

For a detailed interpretation guide, see the Appendix.

6. Performance Characteristics

IKZF1 deletions can be identified in approximately 70% of children with *BCR-ABL1* positive (Philadelphia chromosome, Ph+) ALL (2% of all pediatric ALL cases), in 10-15% of Philadelphia chromosome negative (Ph-) pediatric ALL cases and in 40% of adult B-ALL cases (Bernt and Hunger 2014; Lejman et al. 2022; van der Sligte et al. 2015).

Genomic deletions in *IKZF1* are either whole gene deletions (25-50% of all *IKZF1* deletions; Mullighan et al. 2009; Palmi et al. 2013) or intragenic deletions, with the most frequent intragenic deletion (exons 4-7) comprising 30-55% of all deletions (Kastner et al. 2013, lacobucci et al. 2009). The analytical sensitivity and specificity for the detection of deletions or duplications in the *IKZF1* gene is very high and can be considered >99%.

Analytical performance can be compromised by: SNVs or other polymorphisms in the DNA target sequence, impurities in the DNA sample, incomplete DNA denaturation, the use of insufficient or too much sample DNA, the use of insufficient or unsuitable reference samples, problems with capillary electrophoresis or a poor data normalisation procedure and other technical errors. The MLPA General Protocol contains technical guidelines and information on data evaluation/normalisation.



Content - Probe Details Sorted by Chromosomal Position

Unt. position instruct Exon next probe (m) Probe number Warmage 5533.3 EBF1 Exon 14 65.2 bb 436 1368422053 ¥ 5533.3 EBF1 Exon 1 222 bb 372.1 140591430500 5701.2 IKZF1 Exon 1 226 136774.15918 7012.2 IKZF1 Exon 1 42.4b 280 140591430500 7012.2 IKZF1 Exon 2 8.6 bb 208 14057142113 7012.2 IKZF1 Exon 5 4.8 bb 142 215114.30001 7012.2 IKZF1 Exon 6 4.4 bb 470 140594.32509 7012.2 IKZF1 Exon 6 4.4 bb 470 140544.22151 Y 7012.2 IKZF1 Exon 6 4.4 bb 470 140544.22501 Y 7012.2 IKZF1 Exon 7 9.3 bb 346 344 1344.22631 Y Y 7012.2 <th></th> <th>T</th> <th>F</th> <th>Distance to</th> <th>Length</th> <th>Decksonster</th> <th>w</th>		T	F	Distance to	Length	Decksonster	w
	Chr. position	Target	Exon	next probe	(nt)	Probe number	warnings
SG33.3 EBF1 Exon 14 65.2 kb 436 13868-122053 SG33.3 EBF1 Exon 10 322.2 kb 372 14059-130509 SG33.3 EBF1 Exon 1 14.2 kb 269 13877-115018 * TyD12.2 IKZF1 Exon 2 8.6 kb 209 13872-115018 * TyD12.2 IKZF1 Exon 3 74.0 kb 379 15427-12213 * TyD12.2 IKZF1 Exon 6 4.4 kb 42 1513-130001 * TyD12.2 IKZF1 Exon 6 4.4 kb 470 14061-122112 * TyD12.2 IKZF1 Exon 7 9.3 kb 344 13869-132315 ¥ TyD12.2 IKZF1 Exon 7 701451 570 7452432301 * Sp21.3 CONX2A Upstrem (Intron 1](Exon 1) 30.9 kb 252 103343012 0 P Sp13.2 PAX5 Exon 10 42.0 kb 394 17841-422033 * *	5q33.3	EBF1	Exon 16	14.0 kb	463	23047-L32673	¥
bq33.3 LBF1 Exon 10 322.2 kD99-30809 bq33.3 LBF1 Exon 1 14.2 kD 26 1280-113859 7p12.2 IKZF1 Exon 1 14.2 kD 26 1280-113859 7p12.2 IKZF1 Exon 3 74.0 kD 379 15454 7p12.2 IKZF1 Exon 4 5.9 kD 44 13872-115017 7p12.2 IKZF1 Exon 5 4.8 kD 470 14061-122112 7p12.2 IKZF1 Exon 7 9.3 kD 44 14061-122112 7p12.2 IKZF1 Exon 7 9.3 kD 44 14061-122112 7p12.2 IKZF1 Exon 7 9.3 kD 44 1690-123142 9p21.3 CDKN2A Upsteam [intron 1](Exon 1) 30.9 kD 4224312 kP 4 9p13.2 PAX5 Exon 7 4.2 kD 371 1609422323 kP 4 9p13.2 PAX5 Exon 10 4.2 kD 371<17641-22033	5q33.3	EBF1	Exon 14	65.2 kb	436	13868-L22053	
bq33.3 Lbh - I Exon 1 12.2b 12.2b 12.2b 12.2b 12.2b 12.2b 12.2b 12.2b 12.2b 12.7b 12.7b	5q33.3	EBF1	Exon 10	322.2 kb	372	14059-L30509	
Tp12.2 IKZF1 Exon 1 14.2 kb kb 269 1887/-15918 - Tp12.2 IKZF1 Exon 3 74.0 kb 379 14056-11564 - Tp12.2 IKZF1 Exon 3 74.0 kb 379 15454 - Tp12.2 IKZF1 Exon 5 4.8 kb 142 1511-30001 Tp12.2 IKZF1 Exon 6 4.4 kb 70 4061-2212 X Tp12.2 IKZF1 Exon 7 9.3 kb 344 1869-32515 Y Tp12.2 IKZF1 Exon 8 71 kb 309 17814-22631 Y 9p21.3 CDKN2A Upstream [Intron 1[Exon 1] 309 kb 323 16094-22037 9 9p13.2 PAX5 Exon 1 42.0 kb 394 17841-22038 49 9p13.2 PAX5 Exon 5 18.0 kb 221 1370-11520 4 9p13.2 PA	5q33.3	EBF1	Exon 1		226	12509-L13559	
Typi Typi< Typi< Typi Typi <thtypi< th=""> Typi Typi <</thtypi<>	7p12.2	IKZF1	Exon 1	14.2 kb	269	13877-L15918	«
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	/p12.2	IKZF1	Exon 2	8.6 kb	208	14056-L15654	«
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	7p12.2	IKZF I	Exon 3	74.0 KD	3/9	15427-L22113	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	7p12.2	IKZF I	EXON 4	5.9 KD	204	138/3-L1591/ 21511 L20001	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	7p12.2 7p12.2	IKZF I IK7E1	Exon 6	4.0 KU	142	1/061-L20001	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	7p12.2 7p12.2	IKZE1	Exon 7	9.4 KD	3//	13869-1 32515	¥
	7p12.2	IKZF1	Exon 8	9.5 Kb	288	17109-1 20256	Ŧ
12.1.3 CDKN2A Exon 3 7.1 kb 309 17814-L22631 . 9p21.3 CDKN2A Upstream [intron 1] (Exon 1) 30.9 kb 252 10333-J30127 0 P 9p13.2 PAX5 Exon 10 42.0 kb 394 17844-L22633 9p13.2 PAX5 Exon 10 42.0 kb 394 17844-L22633 9p13.2 PAX5 Exon 6 61.6 kb 274 17849-L22037 9p13.2 PAX5 Exon 6 36.1 kb 274 17839-L22036 9p13.2 PAX5 Exon 1 161 17201-1425134 + 9p13.2 PAX5 Exon 1 161 12501-142513 + 12p13.2 ETV6 Exon 1 10.1 kb 301 14060-132514 ¥ 12p13.2 ETV6 Exon 1 10.2 kb 389 14060-132514 ¥ 12p13.2 ETV6 Exon 3 30.3 kb 244 13874-12209 - 12q13.3 BTG1-area 348.50 1789-12025	9n24.1	.IΔK2	Exerte	17 M h	157	07452-1 32509	¥٦
jp:1.3 CDKN2A Upstream [intron 1] (Exon 1) 30.9 kb 252 103334.30.27 Ø P 9p13.2 PAX5 Exon 10 42.0 kb 394 1609+4.30167 9p13.2 PAX5 Exon 10 42.0 kb 394 1609+4.30167 9p13.2 PAX5 Exon 7 43.2 kb 337 17842-122633 9p13.2 PAX5 Exon 6 36.1 kb 202 17839+422036 9p13.2 PAX5 Exon 1 161 12514422036 ≪ 9p13.2 PAX5 Exon 1 10.1 kb 301 14674-15394 ≪ 9p13.2 PAX5 Exon 1 10.1 kb 301 14674-15394 12p13.2 ETV6 Exon 1 10.1 kb 301 14674-15394 12p13.2 ETV6 Exon 1 10.2 4 kb 389 14060-42514 ¥ * 12p13.2 ETV6 Exon 3 30.3 kb 244 13874-17160 12q21.33 BTG1-area 30.2 4 kb 13874-17160	9n21.3	CDKN2A	Exon 3	7.1 kb	309	17814-1 22631	-
9p21.3 CDKN2B Protection 1 15 Mb 239 160594.30167 2 9p13.2 PAX5 Exon 10 42.0 kb 394 178424.22633 9p13.2 PAX5 Exon 8 41.4 kb 274 178404.22037 9p13.2 PAX5 Exon 6 36.1 kb 202 178394.22036 9p13.2 PAX5 Exon 5 18.0 kb 282 138704.15920 9p13.2 PAX5 Exon 1 161 12501.432513 ¥ + 12p13.2 PAX5 Exon 1 0.1 kb 301 14060.432514 ¥ « 12p13.2 ETV6 Exon 1 10.1 kb 301 14060.432514 ¥ « 12p13.2 ETV6 Exon 5 52.3 kb 483 14060.432514 ¥ « 12p13.2 ETV6 Exon 3 30.3 kb 424 13874.2009 ~ 12q21.33 BTG1 area 344.3 kb 1784.17160 ~ 1222.333 ~ 12q21.33 BTG1 Exon 1	9p21.3	CDKN2A	Upstream [Intron 1] (Exon 1)	30.9 kb	252	10333-1 30127	Ø₽
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	9p21.3	CDKN2B	Exon 2	15 M b	239	16059-L30167	2.
9p13.2 PAX5 Exon 6 41.4 kb 274 17840-L22037 9p13.2 PAX5 Exon 7 43.2 kb 337 17841-L22036 9p13.2 PAX5 Exon 6 36.1 kb 202 17839-L22036 9p13.2 PAX5 Exon 5 180. kb 222 13870-L15920 « 9p13.2 PAX5 Exon 1 10.1 kb 2114647-L15394 ((9) 9p13.2 PAX5 Exon 1 0.1 kb 301 14058-L15920 « 12p13.2 ETV6 Exon 1 0.1 kb 301 14058-L15926 « 12p13.2 ETV6 Exon 2 86.6 kb 401 13874-L7160 (12p13.2 ETV6 Exon 5 22.3 kb 485 13871-L22009 - 12q21.33 BTG1 area 348.3 kb 178 18021-L22630 - 12q21.33 BTG1 Exon 1 232 21378-L30126 - 12q21.33 BTG1 Exon 1 232 21378-L30126 -	9n13.2	PAX5	Exon 10	42.0 kb	394	17842-1 22633	
9p13.2 PAX5 Exon 7 43.2 kb 337 17841-L22038 9p13.2 PAX5 Exon 6 36.1 kb 202 17839-L22036 9p13.2 PAX5 Exon 5 18.0 kb 282 13870-115920 « 9p13.2 PAX5 Exon 1 161 12501-L32513 ¥ + 12p13.2 PAX5 Exon 1 101 kb 301 14058-L15656 « 12p13.2 ETV6 Exon 1 102.4 kb 389 14060-L32514 V « 12p13.2 ETV6 Exon 1 102.4 kb 389 14060-L32514 V « 12p13.2 ETV6 Exon 3 30.3 kb 244 13871-L2209 13871-L2209 12p13.2 ETV6 Exon 3 30.3 kb 18021-L22630 ~ 12q21.33 BTG1-area 348.3 kb 178 180221-L22630 ~ 12q21.33 BTG1 Exon 2 1.6 kb 330 12535-L22632 # 13q14.2 RB1 Intron 13 (E	9p13.2	PAX5	Exon 8	41.4 kb	274	17840-L22037	
$9p13.2$ PAXSExon 6 36.1 kb 202 $17839-122036$ $9p13.2$ PAXSExon 2 13.6 kb 282 $17839-122036$ $9p13.2$ PAXSExon 2 13.6 kb 172 $14647-15394$ $9p13.2$ PAXSExon 1 10.1 kb 301 $14058-15533$ $\Psi +$ $12p13.2$ ETV6Exon 1 0.1 kb 301 $14058-15656$ ϵ $12p13.2$ ETV6Exon 1 102.4 kb 389 $14060-132514$ $\Psi =$ $12p13.2$ ETV6Exon 2 86.6 kb 401 $13875-122014$ $\Psi =$ $12p13.2$ ETV6Exon 3 30.3 kb 244 $13874-12706$ $12p13.2$ ETV6Exon 5 22.3 kb 485 $13871-122009$ $12p13.2$ ETV6Exon 8 79 Mb 196 $17838-122035$ $12q21.33$ BTG1-area 348.3 kb 178 $18021-122630$ \neg $12q21.33$ BTG1Exon 2 1.6 kb 300 $18022+12263$ \neg $12q21.33$ BTG1Exon 1 232 $21378-30126$ \neg $13q14.2$ RB1Intron 13 (Exon 14) 76.9 kb 335 $01792-12295$ $13q14.2$ RB1Intron 23 (Exon 24) 3.8 kb 427 $01797-16909$ $3q14.2$ RB1Exon 12 1.6 kb 356 $01792-12295$ $13q14.2$ RB1Intron 3 (Exon 14) 76.9 kb 316 $1389-11522$ $13q14.2$ RB1Exon 26 4457 $01797-16909$	9p13.2	PAX5	Exon 7	43.2 kb	337	17841-L22038	
9p13.2PAX5Exon 518.0 kb28213870-15920 ϵ 9p13.2PAX5Exon 11016112501-12513¥ +12p13.2PAX5Exon 10.1 kb30114054-1539412p13.2ETV6Exon 110.1 kb30114058-15656 ϵ 12p13.2ETV6Exon 1102.4 kb38914060-132514¥ ϵ 12p13.2ETV6Exon 286.6 kb40113875-12201412p13.2ETV6Exon 330.3 kb24413874-1716012p13.2ETV6Exon 522.3 kb48513871-12200912p13.2ETV6Exon 879 Mb19617838-1220312q21.33BTG1-area348.3 kb17818021-122630 \neg 12q21.33BTG1Exon 123221378-130126 \neg 12q21.33BTG1Exon 123221378-130126 \neg 13q14.2RB1Exon 630.2 kb22001782-12205 \emptyset 13q14.2RB1Intron 13 (Exon 14)76.9 kb31501789-122025 \emptyset 13q14.2RB1Intron 23 (Exon 24)3.8 kb44501799-101362xp22.337 Vp11.32CRLF2 (PAR1)93.0 kb13613892-154271 f xp22.337 Vp11.32CRLF2 (PAR1)1.3 Mb1441366-13892-15221 f xp22.337 Vp11.32CRLF2 (PAR1)1.3 Mb13613891-154271 f xp22.337 Vp11.32CRLF2 (PAR1)1.3 Mb14457-1152	9p13.2	PAX5	Exon 6	36.1 kb	202	17839-L22036	
$p_{p13.2}$ $PAX5$ Exon 2 13.6 kb 172 $14647.L15394$ $p_{p13.2}$ $PAX5$ $Exon 1$ 161 $12501.L32513$ $\forall +$ $12p13.2$ $ETV6$ $Exon 1$ 0.1 kb 301 $14068.L15656$ \ast $12p13.2$ $ETV6$ $Exon 1$ 102.4 kb 389 $14060.L32514$ $\forall *$ $12p13.2$ $ETV6$ $Exon 2$ 86.6 kb 401 $13875.L22014$ $12p13.2$ $ETV6$ $Exon 3$ 30.3 kb 244 $13874.L7160$ $12p13.2$ $ETV6$ $Exon 5$ 22.3 kb 485 $13871.L22009$ $12p13.2$ $ETV6$ $Exon 8$ 79 Mb 196 $17838.L22035$ $12q21.33$ $BTG1$ -area 348.3 kb 178 $18021.L22630$ \neg $12q21.33$ $BTG1$ $Exon 2$ 1.6 kb 330 $18022.L22363$ \neg $12q21.33$ $BTG1$ $Exon 2$ 1.6 kb 330 $1253.L22632$ # $12q21.33$ $BTG1$ $Exon 12$ 1.6 kb 330 $1253.L22632$ # $12q21.33$ $BTG1$ $Exon 19$ 16.8 kb 220 $01782.L01346$ + $13q14.2$ $RB1$ $Exon 19$ 16.8 kb 358 $01792.L2225$ Ø $13q14.2$ $RB1$ $Exon 26$ 445 $01799.L01362$ X $xp22.33/ Yp11.32$ $CRL2$ (PAR1) $Fxon 26$ 445 $01799.L01362$ $xp22.33/ Yp11.32$ $CRL2$ (PAR1) 129.4 kb 351 $13897.L22054$ $\sqrt{1}$ $xp22.33/ $	9p13.2	PAX5	Exon 5	18.0 kb	282	13870-L15920	«
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	9p13.2	PAX5	Exon 2	13.6 kb	172	14647-L15394	
$12p13.2$ $ETV6$ $Exon 1$ $0.1 kb$ 301 $14058 L15656$ ϵ $12p13.2$ $ETV6$ $Exon 1$ $102.4 kb$ 389 $14060 L32514$ $\Psi <$ $12p13.2$ $ETV6$ $Exon 2$ $86.6 kb$ 401 $13875 L22014$ $12p13.2$ $ETV6$ $Exon 3$ $30.3 kb$ 244 $13874 L17160$ $12p13.2$ $ETV6$ $Exon 5$ $22.3 kb$ 485 $13871 L22009$ $12p13.2$ $ETV6$ $Exon 8$ 79 Mb 196 $17838 L22035$ $12q21.33$ $BTG1$ -area $348.3 kb$ 178 $18021 L22630$ \neg $12q21.33$ $BTG1$ -area $55.7 kb$ 409 $18022 L22363$ \neg $12q21.33$ $BTG1$ $Exon 2$ $16.6 kb$ 330 $12253 L22632$ # $12q21.33$ $BTG1$ $Exon 1$ 232 $21378 L30126$ $+$ $13q14.2$ $RB1$ $Intron 13 (Exon 14)$ $76.9 kb$ 315 $01789 L22025$ \emptyset $13q14.2$ $RB1$ $Intron 23 (Exon 24)$ $3.8 kb$ 427 $01797 L16909$ \emptyset $xp22.33/vp11.32$ $CRLF2$ (PAR1) $93.0 kb$ 136 $13892 L15271$ f $xp22.33/vp11.32$ $CRLF2$ (PAR1) $93.0 kb$ 136 $13890 L15271$ f $xp22.33/vp11.32$ $CRLF2$ (PAR1) $129.4 kb$ 351 $13897 L15270$ 4 $xp22.33/vp11.32$ $CRLF2$ (PAR1) $129.4 kb$ 351 $13897 L15270$ 4 $xp22.33/vp11.32$ $CRLF2$ (PAR1) 2144 $13265 L32718$ <	9p13.2	PAX5	Exon 1		161	12501-L32513	¥ +
$12p13.2$ ETV6Exon 1 102.4 kb 389 $14060-L32514$ $\Psi \ll$ $12p13.2$ ETV6Exon 2 86.6 kb 401 $13875-L22014$ $12p13.2$ ETV6Exon 3 30.3 kb 244 $13874-L760$ $12p13.2$ ETV6Exon 5 22.3 kb 485 $13871-L22009$ $12p13.2$ ETV6Exon 8 79 Mb 196 $17838-L22035$ $12q21.33$ BTG1-area 348.3 kb 178 $18021-L22630$ \neg $12q21.33$ BTG1Exon 2 1.6 kb 330 $12531-L22632$ \neg $12q21.33$ BTG1Exon 2 1.6 kb 330 $12531-L22632$ \neg $12q21.33$ BTG1Exon 2 1.6 kb 330 $12553+L22632$ $\#$ $12q21.33$ BTG1Exon 6 30.2 kb 220 $01782-L01346$ $+$ $13q14.2$ RB1Intron 13 (Exon 14) 76.9 kb 315 $01789-L2025$ \emptyset $13q14.2$ RB1Intron 23 (Exon 24) 3.8 kb 427 $0179-L01362$ Y $Xp22.33/$ vp11.32CRLF2 (PAR1)S10.7 kb 149 $05648-L32510$ Ψf $Xp22.33/$ vp11.32CRLF2 (PAR1) 1.3 Mb 184 $17837-L15740$ f $Xp22.33/$ vp11.32CRF2 (PAR1) 1.3 Mb 184 $17837-L15740$ f $Xp22.33/$ vp11.32CRF2 (PAR1) 1.3 Mb 184 $17837-L15740$ f $Xp22.33/$ vp11.32CRF2 (PAR1) 1.3 Mb 184 $17837-L15740$ f Xp	12p13.2	ETV6	Exon 1	0.1 kb	301	14058-L15656	«
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12p13.2	ETV6	Exon 1	102.4 kb	389	14060-L32514	¥ «
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12p13.2	ETV6	Exon 2	86.6 kb	401	13875-L22014	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12p13.2	ETV6	Exon 3	30.3 kb	244	13874-L17160	
12p13.2ETV6Exon 879 Mb19617838-L2203512q21.33BTG1-area348.3 kb17818021-L22630 \neg 12q21.33BTG1Exon 21.6 kb33012553-L22632 \neg 12q21.33BTG1Exon 21.6 kb33012553-L22632 $\#$ 12q21.33BTG1Exon 123221378-L3012613q14.2RB1Exon 630.2 kb22001782-L01346 $+$ 13q14.2RB1Intron 13 (Exon 14)76.9 kb31501799-L2025 \emptyset 13q14.2RB1Intron 23 (Exon 24)3.8 kb42701797-L16909 \emptyset 13q14.2RB1Intron 23 (Exon 24)3.8 kb42701797-L16909 \emptyset 13q14.2RB1Exon 2644501799-L01362XXp22.33/ Vp11.32SHOX-area (PAR1)510.7 kb14905648-L32510 \forall fXp22.33/ Vp11.32CRLF2 (PAR1)93.0 kb13613892-L15621fXp22.33/ Vp11.32CRLF2 (PAR1)12.4 kb35113907-L2294fXp22.33/ Vp11.32P2RY8 (PAR1)1.3 Mb18417837-L15740fXp22.33/ Vp11.32P2RY8 (PAR1)1.3 Mb1441326-L32718 \checkmark 120S0135-L27684 \neg 120S0135-L27684 \neg 121Reference - COL11A121413265-L32718 \checkmark 2p15Reference - COL1A125804534-L220193p12Reference - BEX1350409870-L19465 <td>12p13.2</td> <td>ETV6</td> <td>Exon 5</td> <td>22.3 kb</td> <td>485</td> <td>13871-L22009</td> <td></td>	12p13.2	ETV6	Exon 5	22.3 kb	485	13871-L22009	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12p13.2	ETV6	Exon 8	79 M b	196	17838-L22035	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12q21.33	BTG1-area		348.3 kb	178	18021-L22630	7
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12q21.33	BTG1-area		55.7 kb	409	18022-L22363	-
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12q21.33	BTG1	Exon 2	1.6 kb	330	12553-L22632	#
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	12q21.33	BTG1	Exon 1		232	21378-L30126	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	13q14.2	RB1	Exon 6	30.2 kb	220	01782-L01346	+
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	13q14.2	RB1	Intron 13 (Exon 14)	76.9 kb	315	01789-L22025	Ø
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	13q14.2	RB1	Exon 19	16.8 kb	358	01792-L22295	
13q14.2RB1Exon 2644501799-L01362Xp22.33/ Yp11.32SHOX-area (PAR1)510.7 kb14905648-L32510¥ \int Xp22.33/ Yp11.32CRLF2 (PAR1)93.0 kb13613889-L15427 \int Xp22.33/ Yp11.32CSF2RA (PAR1)41.4 kb16613892-L16221 \int Xp22.33/ Yp11.32IL3RA (PAR1)129.4 kb35113907-L22294 \int Xp22.33/ Yp11.32P2RY8 (PAR1)1.3 Mb18417837-L15740 \int Yp11.31ZFY120\$0135-L27684 \neg 1p21Reference - COL11A121413265-L32718¥2p15Reference - PEX1350409870-L194652q24Reference - PEX1350409870-L163273p12Reference - BBK136414675-L163273p12Reference - GBE149415203-L169783q11Reference - CPOX47814846-L221115p15Reference - SEMA5A45418691-L024767q11Reference - VPS13B41810063-L302609q34Reference - COL5A129510435-L221109q34Reference - CD5A119206941-L3251111q12Reference - CD5A119206941-L3251111q12Reference - CD5A119206941-L3251111q12Reference - CD5A119206941-L3251111q12Reference - CD5A119206941-L32511	13q14.2	RB1	Intron 23 (Exon 24)	3.8 kb	427	01797-L16909	Ø
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	13q14.2	RB1	Exon 26		445	01799-L01362	
Xp22.33/ Yp11.32CRLF2 (PAR1)93.0 kb13613889-L15427 \int Xp22.33/ Yp11.32CSF2RA (PAR1)41.4 kb16613892-L16221 \int Xp22.33/ Yp11.32IL3RA (PAR1)129.4 kb35113907-L22294 \int Xp22.33/ Yp11.32P2RY8 (PAR1)1.3 Mb18417837-L15740 \int Yp11.31ZFY120S0135-L27684 \neg 1p21Reference - COL11A121413265-L32718¥2p15Reference - PEX1350409870-L194652q24Reference - SCN1A25804534-L220193p25Reference - BRK136414675-L163273p12Reference - GBE1449415203-L169783q11Reference - CPOX47814846-L221115p15Reference - SEMA5A45418691-L024767q11Reference - POR12415370-L137628q22Reference - VPS13B41810063-L302609q34Reference - COL5A129510435-L2211011q12Reference - COL5A119206941-L3251111q12Reference - COL5A120242054	Xp22.33/ Yp11.32	SHOX-area (PAR1)		510.7 kb	149	05648-L32510	¥∫
Xp22.33/ Yp11.32CSF2RA (PAR1)41.4 kb16613892-L16221 \int Xp22.33/ Yp11.32IL3RA (PAR1)129.4 kb35113907-L22294 \int Xp22.33/ Yp11.32P2RY8 (PAR1)1.3 Mb18417837-L15740 \int Yp11.31ZFY120S0135-L27684 \neg 1p21Reference - COL11A121413265-L32718¥2p15Reference - PEX1350409870-L194652q24Reference - SCN1A25804534-L220193p25Reference - BRK136414675-L163273p12Reference - GBE149415203-L169783q11Reference - CPOX47814846-L221115p15Reference - SEMA5A45418691-L024767q11Reference - VPS13B41810063-L302609q34Reference - COL5A129510435-L221109q34Reference - BEST119206941-L3251111q12Reference - EBST119206941-L32511YYY </td <td>Xp22.33/ Yp11.32</td> <td>CRLF2 (PAR1)</td> <td></td> <td>93.0 kb</td> <td>136</td> <td>13889-L15427</td> <td>ſ</td>	Xp22.33/ Yp11.32	CRLF2 (PAR1)		93.0 kb	136	13889-L15427	ſ
Xp22.33/ Yp11.32 <i>IL3RA</i> (PAR1)129.4 kb35113907-L22294 \int Xp22.33/ Yp11.32 <i>P2RY8</i> (PAR1)1.3 Mb18417837-L15740 \int Yp11.31 <i>ZFY</i> 120S0135-L27684 \neg 1p21Reference - <i>COL11A1</i> 21413265-L32718¥2p15Reference - <i>PEX13</i> 50409870-L194652q24Reference - <i>SCN1A</i> 25804534-L220193p25Reference - <i>BRK1</i> 36414675-L163273p12Reference - <i>GBE1</i> 49415203-L169783q11Reference - <i>CPOX</i> 47814846-L221115p15Reference - <i>SCMA5A</i> 45418691-L024767q11Reference - <i>POR</i> 12415370-L137628q22Reference - <i>VPS13B</i> 41810063-L302609q34Reference - <i>COL5A1</i> 29510435-L221011q12Reference - <i>BEST1</i> 19206941-L3251Y11g2Reference - <i>BEST1</i> 192XXX<	Xp22.33/ Yp11.32	CSF2RA (PAR1)		41.4 kb	166	13892-L16221	ſ
Xp22.33/ Yp11.32P2RY8 (PAR1)1.3 Mb18417837-L15740 \int Yp11.31ZFY120S0135-L27684 \neg 1p21Reference - COL11A121413265-L32718¥2p15Reference - PEX1350409870-L194652q24Reference - SCN1A25804534-L220193p25Reference - BRK136414675-L163273p12Reference - GBE149415203-L169783q11Reference - CPOX47814846-L221115p15Reference - SEMA5A45418691-L024767q11Reference - POR12415370-L137628q22Reference - VPS13B41810063-L302609q34Reference - CL5A129510435-L221011q12Reference - BEST119206941-L32511Y11g12Reference - BEST119211g12Reference - BEST119200941-L32511YNeference - BEST119200941-L3251YNeference - BEST119200941-L3251YNeference - BEST119200941-L3251	Xp22.33/ Yp11.32	IL3RA (PAR1)		129.4 kb	351	13907-L22294	ſ
Yp11.31 ZFY 120 S0135-L27684 ¬ 1p21 Reference - COL11A1 214 13265-L32718 ¥ 2p15 Reference - PEX13 504 09870-L19465 \$ 2q24 Reference - SCN1A 258 04534-L22019 \$ 3p25 Reference - BRK1 364 14675-L16327 \$ 3p12 Reference - GBE1 494 15203-L16978 \$ 3q11 Reference - CPOX 478 14846-L22111 \$ 5p15 Reference - SEMA5A 454 18691-L02476 \$ 7q11 Reference - POR 124 15370-L13762 \$ 8q22 Reference - VPS13B 418 10063-L30260 \$ 9q34 Reference - CL5A1 295 10435-L22110 ¥ 11q12 Reference - BEST1 192 06941-L32511 ¥	Xp22.33/ Yp11.32	P2RY8 (PAR1)		1.3 M b	184	17837-L15740	ſ
1p21 Reference - COL11A1 214 13265-L32718 ¥ 2p15 Reference - PEX13 504 09870-L19465 2q24 Reference - SCN1A 258 04534-L22019 3p25 Reference - BRK1 364 14675-L16327 3p12 Reference - GBE1 494 15203-L16978 3q11 Reference - CPOX 478 14846-L22111 5p15 Reference - SEMA5A 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - CL5A1 295 10435-L22110 ¥ 11q12 Reference - BEST1 192 06941-L32511 ¥	Yp11.31	ZFY			120	S0135-L27684	7
2p15 Reference - PEX13 504 09870-L19465 2q24 Reference - SCN1A 258 04534-L22019 3p25 Reference - BRK1 364 14675-L16327 3p12 Reference - GBE1 494 15203-L16978 3q11 Reference - CPOX 478 14846-L22111 5p15 Reference - SEMA5A 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - BEST1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	1p21	Reference - COL11A1			214	13265-L32718	¥
2q24 Reference - SCN1A 258 04534-L22019 3p25 Reference - BRK1 364 14675-L16327 3p12 Reference - GBE1 494 15203-L16978 3q11 Reference - CPOX 478 14846-L22111 5p15 Reference - SEMA5A 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - COL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	2p15	Reference - PEX13			504	09870-L19465	
3p25 Reference - BRK1 364 14675-L16327 3p12 Reference - GBE1 494 15203-L16978 3q11 Reference - CPOX 478 14846-L22111 5p15 Reference - SEMA5A 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - COL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	2q24	Reference - SCN1A			258	04534-L22019	
3p12 Reference - GBE1 494 15203-L16978 3q11 Reference - CPOX 478 14846-L22111 5p15 Reference - SEMA5A 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - COL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	3p25	Reference - BRK1			364	14675-L16327	
3q11 Reference - CPOX 478 14846-L22111 5p15 Reference - SEMA5A 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - COL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	3p12	Reference - GBE1			494	15203-L16978	
3p15 Reference - SEMADA 454 18691-L02476 7q11 Reference - POR 124 15370-L13762 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - COL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	3q11	Reference - CPUX			4/8	14840-L22111	
/q11 Reference - POK 124 153/0-L13/62 8q22 Reference - VPS13B 418 10063-L30260 9q34 Reference - COL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥		Reference - SEMASA			404	18091-LU24/6	
oq22 Reference - CoL5A1 416 10003-L30200 9q34 Reference - CoL5A1 295 10435-L22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥	/111	Reference - PUK			124 110	10062-120260	
243+ Reference - BEST1 233 10435-22110 Ψ 11q12 Reference - BEST1 192 06941-L32511 ¥ 15x01 Deference - BEN1 004 00010-100070 ¥	0q22	Reference - COL 5/1			205	10/03-L30200	ພ
11912 Reference CDA11 192 00941-152211 #	<u>รสร</u> 11c10	Reference - RECT1			290	10433-LZZTTU 060/1_L22511	Ψ
	15c21	Reference - ERN1			201	00941-L32311	Ŧ
16p13 Reference - ABAT	16n13	Reference - $\Delta R \Delta T$			130	13867-1 15385	

Probe lengths may vary slightly depending on capillary electrophoresis instrument settings. Please see the most up to date Coffalyser sheet for exact probe lengths obtained at MRC Holland.

The *EBF1*, *IKZF1*, *CDKN2A*, *CDKN2B*, *PAX5*, *ETV6*, *BTG1*, and *RB1* exon numbers are based on MANE Select transcripts. For more information, see the probe sequence document available on the product page at <u>www.mrcholland.com</u>. For *CDKN2A*, probe target exon number according to the MANE Clinical Plus transcript is given in square brackets when it differs from the MANE Select transcript. Annotations of several probes with targets at the edge of or slightly outside the coding region, were altered. The exon numbering from the previous version of this product description is disclosed between brackets.

Chromosomal bands are based on: hg18.



7. Precautions and Warnings

Probe changes

¥ Probe changed in this product version (C2). Minor alteration, no change in sequence detected.

Probe warnings

- These probes are flanking probe, included to help determine the extent of a deletion/duplication. Copy number alterations of flanking probes are unlikely to be related to the condition tested.
- These probes are located in or near a GC-rich region. A low signal can be caused by salt contamination in the DNA sample leading to incomplete DNA denaturation.
- Ø These probes target a sequences outside of the known coding region.
- # The specificity of this probe relies on a single nucleotide difference compared to a related gene or pseudogene. As a result, an apparent duplication of only this probe can be the result of a non-significant single nucleotide sequence change in the related gene or pseudogene.
- The ligation site of these probes is >20 nt away from the nearest exon. For more information, download the probe sequence sheet from the probemixspecific page on <u>www.mrcholland.com</u>.
- f These probes target the PAR1 region, which is present in two copies per cell in both XX females and XY males. Please note that a decrease in signal may also be due to a loss of the Y chromosome in male samples, and mosaic loss of the Y chromosome is a common feature in the blood of elderly men (Gutiérrez-Hurtado et al. 2024). Y chromosome loss can be detected by comparing the PAR1 results to the ZFY probe at 120 nt, and to the Y-specific control fragment at 105 nt. See appendix for more information.
- Ψ In comparison to focal chromosome 9p deletions, including the JAK2, CDKN2A/2B and PAX5 genes, the COL5A1 probe at 9q34.3 is also affected in case of complete chromosome 9 deletions.
- ₽ This probe targets a sequence 138 nt upstream of the CDKN2A MANE Select transcript (NM_000077.5, P16^{INK4A}), and in intron 1, 3.8 kb before exon 2, of the CDKN2A MANE Plus Clinical transcript (NM_058195.4, p14^{ARF}).

Probemix-specific precautions

- This product is not known to contain any harmful agents. Based on the concentrations present, none of the ingredients are hazardous as defined by the Hazard Communication Standard. A Safety Data Sheet (SDS) is not required for this product: none of the ingredients contain dangerous substances at concentrations requiring distribution of an SDS (as per Regulation (EC) No 1272/2008 [EU-GHS/CLP] and 1907/2006 [REACH] and amendments).
- Sample or technical artefacts may appear as a (mosaic) copy number change of the whole/partial gene. Whole/partial gene deletions or duplications should therefore be confirmed by analysis of an independent DNA sample, to exclude false positive results.
- 3. Small changes (e.g. SNVs, small indels) in the sequence targeted by a probe can cause false positive results, even when >20 nt from the probe ligation site. Sequence changes can reduce the probe signal by preventing ligation of the probe oligonucleotides or by destabilising the binding of a probe oligonucleotide to the sample DNA. Deviations detected by this product should be confirmed, and single-probe deviations always require confirmation. Sequencing

of the target region is recommended. Please contact MRC Holland for more information: <u>info@mrcholland.com</u>.

4. Copy number alterations of reference probes are unlikely to be related to the condition tested.

Technique-specific precautions See the <u>MLPA General Protocol</u>.

8. Limitations

Probemix-specific limitations

- 1. The clinical significance of the following findings is not yet fully established: deletions and duplications in *EBF1*, *CDKN2A/2B*, *PAX5*, *ETV6*, *BTG1*, *RB1*, and the PAR1 region.
- Duplication of the *IKZF1* gene is not expected in ALL patient samples, except in the context of larger duplications within or of chromosome arm 7p. Duplication of *IKZF1* is of unknown clinical significance.
- 3. MLPA analysis on tumour samples provides information on the average situation in the cells from which the DNA was extracted. Gains or losses of genomic regions or genes may not be detected if the percentage of tumour cells is low. The minimum percentage of tumour cells required for reliable analysis is 30% (Al Zaabi et al. 2010, Coll-Mulet et al. 2008). We advise using tumour samples with at least 50% tumour cell content. Therefore, tumour samples should be evaluated by a pathologist before the extraction of DNA. See appendix for more information. In addition, subclonality of the aberration affects the final ratio of the corresponding probe(s). Furthermore, there is always a possibility that one or more reference probes *do* show a copy number alteration in a patient sample.

<u>Technique-specific limitations</u> See the <u>MLPA General Protocol</u>.

9. References Cited in this IFU

- Al Zaabi EA et al. (2010). Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience. J Mol Diag. 12:197-203.
- Bernt KM and Hunger SP (2014). Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol. 4:54.
- Coll-Mulet L et al. (2008). Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia. Br J Haematol. 142:793-801.
- Gutiérrez-Hurtado IA et al. (2024) Loss of the Y Chromosome: A Review of Molecular Mechanisms, Age Inference, and Implications for Men's Health. *Int J Mol Sci.* 25(8):4230.
- Iacobucci I et al. (2009). Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMAAL WP). Blood. 114:2159-67.
- Kastner P et al. (2013). Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res. 3:1-13.
- Lejman M et al. (2022). Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukemia in children. Int J Mol Sci. 23:2755.
- Mullighan CG et al. (2009). Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 360: 470-80.

- Palmi C et al. (2013). What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? Haematologica. 98:1226-31.
- Van der Sligte NE et al. (2015). Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Exp Hematol Oncol. 4:23.

Implemented changes in the product description

Version C2-03 – 17 April 2025 (03S)

- Product description adapted to a new template.
- Product is now registered for IVD use in Colombia.
- Product is no longer registered for IVD use in Morocco.
- Description of probe targets at the edge of or slightly outside the coding region has been adjusted. No change in actual target sites.
- Intended purpose was updated adjusting gene name formatting and specifying the assay is manual.
- Warning added for probe 13870-L15920 being located in a GC-rich region.
- SNV rs556167410 can affect the signal of probe 10435-L22110. However, the warning for this SNV present in previous product description versions has been replaced by a general warning for small sequence changes, included in section Precautions and Warnings.
- Information about interpretation of PAR1 region probe signal was moved to a probe warning.

10. Appendix

Interpretation of results: male reference samples

In this probemix, the 120 nt Y-specific target probe (ZFY) is included as a flanking probe to help determine the extent of a deletion in the PAR1 region and to detect loss of the whole Y chromosome in male samples. To ensure that the comparative analysis can be completed for all samples, **only male reference samples must be used**. The comparative analysis will fail if female reference samples are used.

- In male samples, the 120 nt Y-specific target probe will be counted as an "additional" probe when using Coffalyser.Net software (see Figure 1). In healthy male individuals a final ratio of ~1 will be obtained for the Y-specific target probe after the comparative analysis. If the Y chromosome is lost in male samples, rather than deletion of the PAR1 region only, this can also be confirmed by visual examination of the 105 nt Y-fragment peak in the electropherogram (fragment analysis).
- In female samples, the 120 nt Y-specific target probe will be reported as "absent", i.e. will have a final ratio of 0, after the comparative analysis.

sample name	sample type	bin smpl	FRSS	FMRS	prob	es 🗠	DNA	DD	Х	Y
Reference sample 1	reference		al	al	\bigcirc	57/57	\bigcirc	\bigcirc	1	1
Reference sample 2	reference		al	al	\bigcirc	57/57	\bigcirc	\bigcirc	1	1
Reference sample 3	reference		al	al	\bigcirc	57/57	\bigcirc	\bigcirc	\checkmark	*
Sample	sample			. d	\bigcirc	56/56	\bigcirc	\bigcirc	\checkmark	0
noDNA	no DNA				\bigcirc	0/0		۲	۲	

Figure 1. Example fragment analysis overview in Coffalyser.Net with three male reference samples, a female test sample and a no DNA reaction. Note that the number of detected/expected probes differs between male (57/57) and female (56/56) samples.

Interpretation of results: tumour cell percentage and subclonality

In case of a heterozygous deletion that is subclonal and/or the sample contains a lower percentage of tumour cells, the FR might not be in the expected range of 0.40-0.65 (as indicated in the table in section 4, above). For example, in case of ~50% tumour cell content or a copy number alteration present in ~50% of the tumour cells, the FR will be ~0.75. However, the same FR (0.75) will also be found for a sample with a tumour cell percentage of 25% or a subclone comprising 25% of all tumour cells that harbours a homozygous deletion. The MLPA technique cannot discriminate between these two scenarios.

MRC Holland, SALSA, MLPA, digitalMLPA, Coffalyser.Net, Coffalyser digitalMLPA, and their logos are trademarks or registered trademarks of MRC Holland BV. All other brands and names herein are the property of their respective owners.